Perform baseline hepatic laboratory tests to evaluate for hepatic function and injury, including serum alanine aminotransferase (ALT), serum aspartate aminotransferase (AST), serum alkaline phosphatase (ALP) and total and direct serum bilirubin prior to fezolinetant initiation; perform follow-up hepatic laboratory tests monthly for the first 3 months, at 6 months, and 9 months after initiation of therapy
VEOZAH [package insert]. Northbrook, IL, USA: Astellas Pharma, Inc. Available at: https://www.astellas.com/us/system/files/veozah_uspi.pdf.
The medical information on this website is for educational purposes only and is intended to provide scientific information about Astellas products. This information is not intended as medical advice or clinical recommendations. This website is for use only by United States residents and licensed healthcare professionals (HCPs) practicing in the United States. Product labeling may vary between countries.
Please choose an option that best describes you:
For visitors outside the United States: click here